Edgewise Therapeutics, Inc. EWTX Total debt

Total debt at other companies

Bristol-Myers SquibbBMY

$43.33B-12.3%

Sarepta Therapeutics, Inc.SRPT

$198.23M-7.6%

CytokineticsCYTK

$399.03M+31.2%

PTC TherapeuticsPTCT

$395.09M+0.1%

Dyne Therapeutics, Inc.DYN

$168.68M+623%

Solid Biosciences Inc.SLDB

$20.16M-12.6%

FAQ

What is Edgewise Therapeutics, Inc.'s total debt?

Edgewise Therapeutics, Inc. (EWTX) reported total debt of $3.79M in Q1 2026.

How has Edgewise Therapeutics, Inc.'s total debt changed year-over-year?

Edgewise Therapeutics, Inc.'s total debt decreased by 16.8% year-over-year, from $4.56M to $3.79M.

What is the long-term trend for Edgewise Therapeutics, Inc.'s total debt?

Over 3 years (2022 to 2025), Edgewise Therapeutics, Inc.'s total debt has grown at a -3.3% compound annual growth rate (CAGR), from $4.41M to $3.99M.

What does total debt mean?

Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.